A reproductive technology known as mitochondrial replacement therapy or “three-parent IVF” has become the focus of an international for-profit medical tourism industry, with hundreds of women traveling to clinics abroad for the procedure over the past decade. Originally developed to reduce the risk of children inheriting rare mitochondrial diseases, the technique is now being marketed as a solution for age-related fertility problems despite scant scientific evidence supporting its effectiveness for this use.
The procedure, which is illegal in the United States, involves inserting genetic material from a patient and her partner into a donor egg cell that has had its nucleus removed. The stated goal is to provide younger, healthier mitochondria to power embryo development. An Illinois-based company called the International Fertility Group of North America serves as a medical tourism facilitator, connecting patients with clinics in countries including Albania, Mexico, the Bahamas, and the Philippines. The company claims that 34 babies were born through its program as of February 2025 and cites pregnancy success rates exceeding 50 percent, though it has provided no substantiation for these figures.
An investigation into the practice identified significant concerns about the industry’s transparency and scientific rigor. Neither the facilitator company nor its partner clinics have published data in reputable, peer-reviewed journals. The available research suggests the procedure does not work for most older women, as their infertility typically stems from factors other than mitochondrial dysfunction. Leading scientists in the field have characterized marketing claims as misleading, noting that published data lack crucial information and cite implausibly high birth rates.
Former patients of the International Fertility Group report mixed experiences, with some expressing regret after spending thousands of dollars. An investigation also uncovered examples of inadequate record-keeping at clinics providing the procedure and incomplete data published in marginal journals. In at least one case, an ancestry test result raised questions about the genetic source of a child born through the procedure, adding to concerns about the operation’s oversight and safety protocols.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI